Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 22;15(7):1791.
doi: 10.3390/pharmaceutics15071791.

Impact of Intensive Glycemic Treatment on Diabetes Complications-A Systematic Review

Affiliations
Review

Impact of Intensive Glycemic Treatment on Diabetes Complications-A Systematic Review

Juliana Poonoosamy et al. Pharmaceutics. .

Abstract

Diabetes complications can be related to the long duration of the disease or chronic hyperglycemia. The follow-up of diabetic patients is based on the control of chronic hyperglycemia, although this correction, if obtained rapidly in people living with severe chronic hyperglycemia, can paradoxically interfere with the disease or even induce complications. We reviewed the literature describing the impact of the rapid and intense treatment of hyperglycemia on diabetic complications. The literature review showed that worsening complications occurred significantly in diabetic microangiopathy with the onset of specific neuropathy induced by the correction of diabetes. The results for macroangiopathy were somewhat mixed with the intensive and rapid correction of chronic hyperglycemia having a neutral impact on stroke and myocardial infarction but a significant increase in cardiovascular mortality. The management of diabetes has now entered a new era with new therapeutic molecules, such as gliflozin for patients living with type 2 diabetes, or hybrid insulin delivery systems for patients with insulin-treated diabetes. Our manuscript provides evidence in support of these personalized and progressive algorithms for the control of chronic hyperglycemia.

Keywords: HbA1c; cardiovascular events; micro- and macrovascular diabetes complications; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart with information on the results of the research carried out in our review.
Figure 2
Figure 2
Impact of the rapid correction of HbA1c in CN physiopathology.

References

    1. Sun H., Saeedi P., Karuranga S., Pinkepank M., Ogurtsova K., Duncan B.B., Stein C., Basit A., Chan J.C.N., Mbanya J.C., et al. IDF Diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 2022;183:109119. doi: 10.1016/j.diabres.2021.109119. - DOI - PMC - PubMed
    1. Schlesinger S., Neuenschwander M., Barbaresko J., Lang A., Maalmi H., Rathmann W., Roden M., Herder C. Prediabetes and risk of mortality, diabetes-related complications and comorbidities: Umbrella review of meta-analyses of prospective studies. Diabetologia. 2022;65:275–285. doi: 10.1007/s00125-021-05592-3. - DOI - PMC - PubMed
    1. Barnes J.A., Eid M.A., Creager M.A., Goodney P.P. Epidemiology and risk of amputation in patients with diabetes mellitus and peripheral artery disease. Arterioscler. Thromb. Vasc. Biol. 2020;40:1808–1817. doi: 10.1161/ATVBAHA.120.314595. - DOI - PMC - PubMed
    1. Tuttolomondo A., Maida C., Pinto A. Diabetic foot syndrome: Immune-inflammatory features as possible cardiovascular markers in diabetes. World J. Orthop. 2015;6:62–76. doi: 10.5312/wjo.v6.i1.62. - DOI - PMC - PubMed
    1. Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int. J. Surg. 2021;88:105906. doi: 10.1016/j.ijsu.2021.105906. - DOI - PubMed

LinkOut - more resources